Deals
Vaccines deal with Sanofi to propel Translate Bio’s mRNA therapeutics platform
Product Development
Action needed to prevent manufacturing bottlenecks on COVID-19 therapies
Data Bytes: Roche tops list of pharmas running COVID-19 trials
Regulation
FDA pilot project aims to provide symptom data to cancer patients
Myovant eyes third NDA for relugolix after endometriosis readout
Politics, Policy & Law
Scientists warn Trump immigration ‘pause’ will harm biopharma innovation
Tools & Techniques
AI tools against COVID-19: a view from where the rubber hits the road
Gilead gains access to tumor myeloid targets via Pionyr partnership
Data Bytes: Gilead’s 2020 cancer deals take on immuno-oncology from different angles
Finance
June 23 Quick Takes: Illumina selects first biotechs for U.K. accelerator; plus updates from the NASDAQ IPO queue, and venture rounds for Surrozen, Tara
BCIQ Company Profiles
Gilead Sciences Inc.
Pionyr Immunotherapeutics Inc.
BCIQ Target Profiles
Triggering receptor expressed on myeloid cells 1 (TREM1)
Triggering receptor expressed on myeloid cells 2 (TREM2)
Expanded deal provides validation for mRNA platform, $425M up front to advance in-house pipeline
Urgent steps needed to prioritize, expand manufacturing capacity for most promising therapies
A conversation on bias, speed and accuracy in AI approaches against COVID-19
Each of Gilead’s five cancer deals this year have given it a line to a new immuno-oncology approach
